Navigation Links
Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
Date:1/11/2012

f cancer by successfully driving its pipeline of antibody-based therapeutics into the clinic."

Dr Christian Rohlff, CEO of OBT, commented, "I am delighted to welcome Glenn to OBT.  His wealth of relevant clinical and commercial expertise in the oncology and antibody field will be instrumental in helping OBT to transition into a successful clinical development organisation as the company works to enhance the future treatment prospects for cancer patients with no treatment."

Today's announcement follows OBT's recent collaboration with Seattle Genetics, Inc. for the development of antibody drug conjugates (ADCs) for cancer, highlighting OBT's growing recognition in the ADC field.  

About OGAP®

The Oxford Genome Anatomy Project (OGAP®) database represents one of the world's largest proprietary collections of disease-associated proteins. OGAP® oncology contains proteomic data on over 7,500 cancer membrane proteins combined with genomic and clinical information derived from human blood and cancer tissue studies. OGAP® contains proprietary target information on three-quarters of the entire human proteome. Almost two million human protein fragments have been sequenced in OGAP® in 50 different human tissues representing 60 diseases, including 25 forms of cancer. OGAP® integrates data covering 17,000 different genes and over eight million genetic variants (SNPs and haplotypes).

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on the development and commercialization of innovative antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. OBT accesses leading antibody technologies and expertise through its partnerships with many of the world leaders in antibody development, including BMS (Medarex), Amgen, Alere (formerly Biosite) and BioWa,
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
2. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
3. Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
4. Oxford Finance Corporation Sponsors 2010 Mid-Atlantic Bio
5. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
6. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
7. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
8. Oxford BioTherapeutics Appoints Michael Moore as Chairman
9. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
10. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
11. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO ... a conference call and webcast on Friday, October 2, ... update investors on the Company,s Phase 3 program for ... dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will ...
... Enerkem,s future biofuels plant will supply green energy to ... - Enerkem, a leading waste-to-biofuels and green chemicals technology company, ... that will heat a Strathcona County neighbourhood, using the residual ... Edmonton waste-to-biofuels plant. , The project received grant funding in ...
... YORK, Oct. 1 /PRNewswire-FirstCall/ - Healthnostics, Inc. (OTC PK: ... its strategy for the biomedical content layer of the ... major shift in strategy by MedBioWorld.com will consist of ... professional base to a wider, more general audience. This ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call 2Enerkem Announces Unique Community Energy Project 2Healthnostics Unveils Biomedical Content Strategy for Medbioworld.com 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... renowned climate researcher Caroline Leck of Stockholm University has ... results are truly sensational," says Dr Leck. "If confirmed ... efforts to achieve the political targets for climate." ... Earth,s mean surface temperature climbed sharply through the 1990s, ...
... one of the leaders in the field of neurosciences, ... of one of literature,s greatest authors, Virginia Woolf. The ... the literature she wrote and comments, letters and other ... medical status. The author uses current insights into depression, ...
... 25, 2013 /PRNewswire-iReach/ --   Find Heather on ... . She is a a third year physics major at the ... also learned after writing numerous twenty plus page lab reports, a life ... a career relating to patents and IP law. Last summer, she interned ...
Cached Biology News:Global warming less extreme than feared? 2Global warming less extreme than feared? 3Global warming less extreme than feared? 4The Website You Have to Log Into 2The Website You Have to Log Into 3
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
Biology Products: